Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-21-000251
Filing Date
2021-01-06
Accepted
2021-01-06 21:43:22
Documents
1
Period of Report
2021-01-04

Document Format Files

Seq Description Document Type Size
1 form4-01062021_060114.html 4  
1 form4-01062021_060114.xml 4 3945
  Complete submission text file 0001415889-21-000251.txt   5472
Mailing Address 1615 SOUTH CONGRESS AVENUE SUITE 103 DELRAY BEACH FL 33445
Business Address 1615 SOUTH CONGRESS AVENUE SUITE 103 DELRAY BEACH FL 33445 646-699-7855
AzurRx BioPharma, Inc. (Issuer) CIK: 0001604191 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217 BROOKLY NY 11226
Business Address
Riddell Alastair (Reporting) CIK: 0001681349 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37853 | Film No.: 21512864